Dementia and Alzheimer Disease

Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 25, 2023.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicole Fowler. [LISTEN TIME: 23 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 18, 2023.

Adam Naj, PhD, genetic epidemiologist at the University of Pennsylvania, discussed the importance of collecting genetic data from diverse ancestries to investigate the risk of Alzheimer Disease.

The senior vice president of research at Vaxxinity discussed recently published trial findings on a novel vaccine that targets Alzheimer disease and triggers the production of antibodies against toxic amyloid-ß peptides. [WATCH TIME: 9 minutes]

Foralumab, a therapy designed to bind to T cell receptor, is about to be assessed in phase 2 trials of patients with non-active secondary progressive multiple sclerosis in the third quarter of 2023.

Results indicated a substantial direct effect of air pollution on dementia suggesting that air pollution affects the development of dementia through multiple pathways.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology.

UB-311 elicited a robust, rapid, and titrated antibody response to amyloid-ß, with an overall 97% responder rate that was maintained by 93% of the cohort by the end of the 78-week study.

Neurology News Network for the week ending August 12, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 11, 2023.

Pharmacokinetic results indicated that ACD856 has a suitable pharmacokinetic profile for further development with a rapid absorption, dose-dependent exposure, and a favorable metabolic profile.

The double-blind, placebo-controlled trial assesses change from baseline in the weekly average of daily self-reported worst pain intensity scores after 14 weeks of treatment.

Catch up on any of the neurology news headlines you may have missed over the course of July 2023, compiled all into one place by the NeurologyLive® team.

The associate professor of neurology at the Indiana University School of Medicine discussed the screening paradigm for Alzheimer disease, and the reluctancy to use new digital tools over traditional methods. [WATCH TIME: 6 minutes]

Concentrations of Aß42 and Aß40 were substantially higher in those with amyloid-ß-negative, tau-positive status compared with Aß-negative, tau-negative patients.

Here's some of what is coming soon to NeurologyLive® this week.

As a recap from AAIC 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.